SAMe (S-Adenosyl Methionine) — Frequently Asked Questions
This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer
Frequently Asked Questions
Is SAMe as effective as ibuprofen for joint pain?
Is SAMe as effective as ibuprofen for joint pain?
Clinical evidence says yes. Multiple head-to-head trials and a meta-analysis of 11 RCTs found SAMe equivalent to NSAIDs including ibuprofen for osteoarthritis pain, with a significantly better side effect profile — particularly regarding GI tolerability. The main tradeoff is slower onset (2-4 weeks vs. hours).
Why is SAMe so expensive compared to other joint supplements?
Why is SAMe so expensive compared to other joint supplements?
SAMe is inherently unstable and requires careful manufacturing (enteric-coated tablets, blister packaging, cold storage) to prevent degradation. The required daily dose (600-1,200mg) is also relatively high. Look for reputable brands with enteric-coated, individually sealed tablets to ensure you are getting active SAMe.
Can SAMe help with both joint pain and depression?
Can SAMe help with both joint pain and depression?
Yes, SAMe has strong evidence for both conditions. It is a methyl donor involved in neurotransmitter synthesis (supporting mood) and cartilage metabolism (supporting joints). For patients with OA and comorbid mild-to-moderate depression, SAMe at 1,200mg daily may address both issues simultaneously.
References
- Soeken KL, Lee WL, Bausell RB, et al. (2002). Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. Journal of Family Practice. PubMed
- Najm WI, Reinsch S, Hoehler F, et al. (2004). S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskeletal Disorders. DOI PubMed
- Kim J, Lee EY, Koh EM, et al. (2009). Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis. Journal of Korean Medical Science. DOI PubMed
- Hardy ML, Coulter I, Morton SC, et al. (2003). S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment (AHRQ). PubMed